$CETY

Clean Energy Technologies, Inc. (CETY): Entry into a Material Definitive Agreement

Clean Energy Technologies, Inc. (CETY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 SUBORDINATED BUSINESS LOAN AND SECURITY AGREEMENT THIS SUBORDINATED BUSINESS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, modified, or supplemented from time to time, this “ Agreement ”) dated as of May 27, 2026(the

Original reporting
Published Jun 8, 2026, 10:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 8:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CETY
Neutral
medium confidence
Mentioned
$CETY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CETYNeutralMed
01

Why it matters

The disclosure signals a new financing facility and associated repayment/interest obligations, with potential credit-risk implications if covenants or maturity/repayment terms are tight. The make-whole premium and default-rate provisions increase downside in stress scenarios.

02

Market read

Material definitive financing documentation can reprice perceived leverage and liquidity risk for small-cap issuers, especially when terms/covenants are not yet fully digested by the market.

03

What to watch

Traders will need the missing exhibits (e.g., Exhibit B-4 repayment schedule, B-5 interest rate, and any covenant/security details) to judge whether this is manageable liquidity support or a higher-risk leverage step-up.

Relevance 6/10Novelty 8/10Timing: Filed June 8, 2026 (SEC 8-K)

Background

The 8-K reports CETY’s entry into a Subordinated Business Loan and Security Agreement dated May 27, 2026, with a collateral agent and lead lender, and includes provisions for term loan repayment, interest, default rate, and make-whole prepayment fees.

Company-level read

Ticker impact

$CETYNeutralMedium confidence
Context

CETY filed an 8-K disclosing entry into a Subordinated Business Loan and Security Agreement, creating new direct financial obligations.

Expected impact

Likely modest negative-to-neutral near-term bias as leverage/financing risk rises, with sensitivity to loan terms and any disclosed covenants.

Evidence & confidence

The filing confirms a new material definitive financing agreement (Item 1.01/2.03) but the excerpt does not provide principal size, maturity, or covenant details that would sharpen magnitude of impact.

Market effects

Adds a data point on how small-cap clean-energy issuers are funding operations via subordinated secured debt structures.

No clear regional read-through beyond US small-cap credit conditions.

Limited; this is company-specific financing documentation.

Counterpoint

If the loan replaces more expensive or dilutive funding, the net effect could be neutral or even supportive despite the “obligation” framing.

Key entities

  • Clean Energy Technologies, Inc.

    Borrower/parent entering the subordinated business loan and security agreement disclosed in the 8-K.

  • Agile Lending, LLC

    Lead lender under the subordinated business loan agreement.

  • Agile Capital Funding, LLC

    Collateral agent named in the agreement.

Related articles

$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

$ABTMed

Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update

Abbott Laboratories plans to separate its nutrition business, with $8.5B in annual sales, into an independent company by 2027. The move aims to focus on higher-growth areas. Shares fell 4% premarket. Q3 sales rose 14% to $13.01B, but profit declined due to higher costs. Abbott faces ongoing litigation over its baby-formula facility and has agreed to multimillion-dollar settlements.